abstract |
The invention relates to a new class of sulfonamides that are inhibitors of aspartyl protease. The invention relates to a new class of HIV aspartyl-protease inhibitors, characterized by specific structural and physicochemical characteristics. The invention also relates to pharmaceutical compositions containing these compounds. The compounds and pharmaceutical compositions of the present invention are particularly suitable for inhibiting HIV-1 and HIV-2 protease activity and, accordingly, can be advantageously used as antiviral agents against HIV-1 and HIV-2 viruses. The invention also relates to methods for inhibiting HIV aspartyl protease activity by using the compounds of the present invention, and methods for screening compounds for their anti-HIV activity. |